0LQI Stock Chart & Stats
$74.80
$0.00(0.00%)
At close: 4:00 PM EDT
$74.80
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$74.80 - $74.80
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$178.88M
Enterprise Value$498.91
Total Cash (Recent Filing)$155.10M
Total Debt (Recent Filing)$567.00K
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Oct 29, 2026EPS Estimate
-0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.80
Shares Outstanding13,644,467
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-12.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.97
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$39.14Price Target Upside-47.67% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Improved EquityMinimal debt and materially improved TTM equity give Immunic a comparatively light capital structure. This reduces interest-related pressure and preserves financial flexibility for clinical development, although continued losses could erode the equity base if funding needs remain high.
Late-stage MS PipelineThe late-stage vidofludimus calcium program provides a defined development path toward potential regulatory filings and commercialization. Progress across relapsing and progressive MS could broaden the addressable opportunity and create a more durable foundation than earlier-stage research alone.
Commercial-readiness CapabilitiesEstablishing a dedicated data and digital leadership function supports Immunic’s transition from late-stage clinical development toward commercial readiness. Stronger analytics, data management, and digital infrastructure can improve organizational scalability as programs advance toward regulatory and launch activities.
Bears Say
No Revenue And Persistent LossesImmunic remains entirely pre-commercial, with no reported revenue and substantial recurring losses. Until a product reaches the market, the company lacks operating income to fund research and development, leaving earnings power dependent on successful clinical execution and eventual commercialization.
High Cash Burn And Financing DependencePersistent negative operating and free cash flow indicates that Immunic consumes substantial cash while advancing its pipeline. This limits internal funding capacity and means continued access to external financing remains important until revenue begins or spending is materially reduced.
Potential Equity DilutionExpanding the equity incentive pool may help attract and retain specialized biotechnology talent, but it also creates potential dilution for existing shareholders. The effect is especially relevant while Immunic has no product revenue and relies on equity-linked funding and compensation.
Immunic News
0LQI FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest share price was $74.80 and its highest was $74.80 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $178.88M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is Oct 29, 2026 which is in 52 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Aug 11, 2026. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.165 by $0.365.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Overvalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate is -0.97.
How many shares outstanding does Immunic have?
Immunic has 13,644,467 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.165. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in GB:0LQI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.14 (-47.67% Downside)
$39.14 (-47.67% Downside)
Blogger Sentiment
Bullish
GB:0LQI Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
159.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunic
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
0LQI Stock 12 Month Forecast
Average Price Target
$39.14
▼(-47.67% Downside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―